Zevra Therapeutics

ZEVRA THERAPEUTICS INC

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

blur-1853262

News

ZVRA

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results.

Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What&#39;s Going On?

zvra

Biotech

Health Care

General

The FDA has approved Zevra Therapeutics&#39; Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.

Zevra Therapeutics&#39; Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Nikola Motor

Intraday Update

Markets

Movers

Trading Ideas

ALTS

ALZN

APDN

APPS

CING

CLOV

FFIE

FHTX

FUBO

GNLN

GOVX

IBRX

INZY

LLAP

LQDA

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NKLA

SEEL

SIDU

SOND

TELO

TGTX

TNXP

TOVX

VALN

VRAX

XPER

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Zevra Therapeutics Inc

Earnings

Press Releases

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Zevra Therapeutics Files Preliminary Proxy

Contracts

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Analyst Ratings

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

Zevra Therapeutics to Participate in the Citizens Life Science Conference

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

ATAI Life Sciences

Cronos Group

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LENZ Therapeutics

Maze Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nuvation Bio

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Cantor Fitzgerald

Canaccord Genuity

Guggenheim

HC Wainwright & Co.

Citizens Capital Markets

Comments

Zevra Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell